Perjeta

Chemical Namepertuzumab
Dosage FormInjection (intravenous; 420mg/14mL)
Drug ClassReceptor antagonists
SystemFemale reproductive
CompanyGenentech Inc.
Approval Year2012

Indication

  • Indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
  • Indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
  • Indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
Last updated on 5/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Perjeta (pertuzumab) Prescribing Information2012Genentech Inc., South San Francisco, CA